Transurethral resection of the prostate achieves favorable outcomes in stroke patients with symptomatic benign prostate hyperplasia

Figures & data

Table 1. Patient characteristics in nonstroke and stroke groups.

	Non-stroke	Stroke
Variable	(n = 6048)	(n = 577)	p value
Age (mean ± SD)	71.9 ± 8.3	74.1 ± 7.9	<.001
UTI within 3 months (%)	1112 (18.4)	160 (27.7)	<.001
Urine retention within 3 months (%)	2075 (34.3)	275 (47.7)	<.001
Comorbidity (%)
Diabetes mellitus	767 (12.7)	144 (25.0)	<.001
Dyslipidemia	525 (8.7)	69 (12.0)	.008
Hypertension	1996 (33.0)	359 (62.2)	<.001
Parkinsonism	80 (1.3)	26 (4.5)	<.001
Chronic obstructive pulmonary disease	644 (10.6)	91 (15.8)	<.001
Ischemic heart disease	770 (12.7)	107 (18.5)	<.001
Heart failure	167 (2.8)	39 (6.8)	<.001
Tissue ablation (%)			.003
5–15 g	4458 (73.7)	399 (69.2)
15–50 g	1330 (22.0)	161 (27.9)
>50 g	260 (4.3)	17 (2.9)
Medication within 3 months (%)
Anti-muscarinic	574 (9.5)	66 (11.4)	.130
α-Blocker	4583 (75.8)	450 (78.0)	.235
Bethanechol	862 (14.3)	110 (19.1)	.002
Any urologic drug	4681 (77.4)	464 (80.4)	.096
Follow up years	6.9 ± 4.4	5.0 ± 3.8	<.001

UTI: urinary tract infection.

Table 2. Clinical postoperative outcomes in nonstroke and stroke groups.

	Non-stroke	Stroke	Stroke vs. non-stroke
Variable	(n = 6048)	(n = 577)	aOR (95% CI)^a	p value
UTI (%)
< 1 month	1277 (21.1)	151 (26.2)	1.07 (0.87–1.32)	.498
1 month – 1 year	1229 (20.3)	172 (29.8)	1.37 (1.13–1.68)	.002
Urine retention (%)
<1 month	607 (10.0)	94 (16.3)	1.50 (1.18–1.92)	.001
1 month to 1 year	723 (12.0)	130 (22.5)	1.89 (1.51–2.36)	<.001
In hospital death (%)	7 (0.1)	6 (1.0)	8.27 (2.47–27.70)	.001
Re-open of TURP (%)	422 (7.0)	24 (4.2)	0.66 (0.43–1.02)	.061

aOR: adjusted odds ratio; CI: confidence interval; UTI: urinary tract infection.

^a Adjustment for age, UTI during 3 months preoperatively, urine retention during 3 months preoperatively, diabetes mellitus, dyslipidemia, hypertension, Parkinson disease, chronic obstructive pulmonary disease, ischemic heart disease, heart failure, tissue ablation, preoperative medication use (yes or no).

Figure 1. Risk of urologic drug use in nonstroke and stroke groups during various follow-up periods.

Figure 2. Adjusted medication-free survival curves in nonstroke and stroke groups (A) and hemorrhagic and ischemic stroke groups (B) during follow-up.

Figure 3. UTI and UR rates during 1 year before and after TURP in the nonstroke and stroke groups.

Figure 4. UTI and UR rates during 1 year before and after TURP in ischemic and hemorrhagic stroke groups.

Figure 5. Medical expenses before and after TURP in the nonstroke and stroke groups.